AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b

AnaCardio reported strong Phase 2a topline data for AC01 in HFrEF showing a favorable safety and tolerability profile and consistent, rapid exploratory signals of improved hemodynamics and cardiac structure/function in a randomized 26‑patient, 28‑day study (1 mg and 3 mg vs. placebo). There were no treatment‑emergent adverse events leading to discontinuation, no drug‑related serious adverse events, no ischemia or sustained arrhythmias, predictable dose‑proportional pharmacokinetics and dose‑dependent target engagement (growth hormone release). While the study was not powered for efficacy, these results justify rapid advancement into a larger Phase 2b expected to start mid‑2026 and materially de‑risk the company’s first‑in‑class oral calcium‑sensitizing ghrelin‑agonist approach as a potential differentiated therapy for chronic HFrEF.

Analysis

AnaCardio reported topline results from the Phase 2a portion of GOAL-HF1 in 26 HFrEF patients randomized to 1 mg, 3 mg AC01 or placebo twice daily for 28 days across 13 European centers, and plans to advance to a larger Phase 2b anticipated to start mid-2026. The trial was not powered for efficacy, yet exploratory assessments showed consistent, rapid and sustained improvements in hemodynamics and cardiac structure/function over 28 days, providing initial efficacy signals that management cites as justification for rapid progression.

Safety and pharmacology data materially underpin the announcement: there were no treatment-emergent adverse events leading to discontinuation, no drug-related serious adverse events, no ischemia or new sustained arrhythmias, and no clinically relevant blood-pressure effects; pharmacokinetics were predictable and dose-proportional and target engagement was demonstrated by dose-dependent growth-hormone release. These observations align with the drug’s proposed ghrelin-receptor calcium-sensitizing mechanism and differentiate AC01 from conventional inotropes.

Key implications are measured de-risking on safety/PK and biomarker fronts but persistent uncertainty on clinical efficacy due to small sample size, short duration and exploratory endpoints. The Phase 2b design, size, endpoints and longer-term safety data will be decisive for valuation, partnering interest and commercialization prospects given AnaCardio’s exclusive license from Helsinn and ~USD40m raised to date.

Key Decisions for Investors

• Monitor the Phase 2b protocol and enrollment timeline (mid-2026 start) closely — sample size, primary endpoints and treatment duration will determine whether exploratory signals can be converted into a registrational pathway
• Require confirmation of durable efficacy and maintained safety (absence of ischemia/arrhythmia and stable blood pressure) in a larger, longer trial before materially increasing exposure to AnaCardio, given Phase 2a’s small N and short follow-up
• Consider opportunistic, limited exposure in private or partnership rounds if available given favorable safety/PK de-risking and exclusive Helsinn license, but size positions conservatively and hedge against binary clinical outcomes
• Watch for external validation events (independent data readouts, DSMB reports, or strategic partnerships) and use those milestones to re-evaluate valuation and commercial probability rather than relying on Phase 2a exploratory endpoints